This area of the website contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules. This information is not directed to nor is it intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.
Oncimmune’s ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients.
Oncimmune is headquartered in the UK, listed on AIM, its lab is in Dortmund, Germany and salesforce is global.
Simon Bonney and James Varney of Arafino Advisory Limited were appointed Joint Administrators of Oncimmune Holdings PLC (“the Company”) on 26 March 2025.
The affairs, business and property of the Company are managed by the Joint Administrators. The Joint Administrators act as agents of the Company and contract without personal liability.
Simon Bonney and James Varney are authorised to act as insolvency practitioners by the Insolvency Practitioners Association and are bound by the Insolvency Code of Ethics.
If any party requires further information regarding the Administration process or is interested in acquiring any assets of the Company, please contact the Joint Administrators at ONC@arafino.com.